Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 2,905

The DOI matches its Crossref record; 479 of the 479 references it cites were found in a registry or an index.

EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis

Open access
Angeli, Paolo, Bernardi, Mauro, Villanueva, Càndid, Francoz, Claire, Mookerjee, Rajeshwar P., Trebicka, Jonel, Krag, Aleksander, Laleman, Wim, Gines, Pere · 2018 · Journal of Hepatology

Abstract

Summary The natural history of cirrhosis is characterised by an asymptomatic compensated phase followed by a decompensated phase, marked by the development of overt clinical signs, the most frequent of which are ascites, bleeding, encephalopathy, and jaundice. The following Clinical Practice Guidelines (CPGs) represent the first CPGs on the management of decompensated cirrhosis. In this context, the panel of experts, having emphasised the importance of initiating aetiologic treatment for any degree of hepatic disease at the earliest possible stage, extended its work to all the complications of cirrhosis, which had not been covered by the European Association for the Study of the Liver guidelines, namely: ascites, refractory ascites, hyponatremia, gastrointestinal bleeding, bacterial infections, acute kidney injury, hepatorenal syndrome, acute-on-chronic liver failure, relative adrenal failure, cirrhotic cardiomyopathy, hepatopulmonary syndrome, and porto-pulmonary hypertension. The panel of experts, produced these GPGs using evidence from PubMed and Cochrane database searches providing up to date guidance on the management of decompensated cirrhosis with the only purpose of improving clinical practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2018.03.024

Cites

479 of 479 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Items 401–479 of 479

Research works printed but not linked: 130

  1. Arroyo, 2007, Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome, J Hepatol, 46, 935, 10.1016/j.jhep.2007.02.001 · doi:10.1016/j.jhep.2007.02.001
  2. Alvarez, 2011, Long-term clinical course of decompensated alcoholic cirrhosis: a prospective study of 165 patients, J Clin Gastroenterol, 45, 906, 10.1097/MCG.0b013e3182284e13 · DOI
  3. Moreau, 2017, A randomized trial of 6-month norfloxacin therapy in patients with Child-Pugh class C cirrhosis, J Hepatol, 66, S1, 10.1016/S0168-8278(17)30264-7 · doi:10.1016/s0168-8278(17)30264-7
  4. Sola, 2017, Midodrine and albumin for prevention of complications of cirrhosis in patients in the waiting list for liver transplantation. A randomized, multicenter, double-blind, placebo-controlled trial, J Hepatol, 66, S11, 10.1016/S0168-8278(17)30285-4 · doi:10.1016/s0168-8278(17)30285-4
  5. Gerbes, 1991, Ascitic fluid analysis for the differentiation of malignancy-related and nonmalignant ascites. Proposal of a diagnostic sequence, Cancer, 68, 1808, 10.1002/1097-0142(19911015)68:8<1808::AID-CNCR2820680827>3.0.CO;2-6 · doi:10.1002/1097-0142(19911015)68:8<1808::aid-cncr2820680827>3.0.co;2-6
  6. Biselli, 2015, A new prognostic model to predict dropout from the waiting list in cirrhotic candidates for liver transplantation with MELD score <18, Liver Int, 35, 184, 10.1111/liv.12538 · doi:10.1111/liv.12538
  7. Lin, 2005, Should bleeding tendency deter abdominal paracentesis?, Dig Liver Dis, 37, 946, 10.1016/j.dld.2005.07.009 · doi:10.1016/j.dld.2005.07.009
  8. Cabrera, 1982, Aminoglycoside nephrotoxicity in cirrhosis. Value of urinary beta 2-microglobulin to discriminate functional renal failure from acute tubular damage, Gastroenterology, 82, 97, 10.1016/0016-5085(82)90129-9 · doi:10.1016/0016-5085(82)90129-9
  9. Guevara, 2004, Effects of contrast media on renal function in patients with cirrhosis: a prospective study, Hepatology, 40, 646, 10.1002/hep.20373 · doi:10.1002/hep.20373
  10. Saab, 2006, TIPS vs. paracentesis for cirrhotic patients with refractory ascites, Cochrane Database Syst Rev, CD004889
  11. Gaba, 2015, Survival benefit of TIPS vs. serial paracentesis in patients with refractory ascites: a single institution case-control propensity score analysis, Clin Radiol, 70, e51, 10.1016/j.crad.2015.02.002 · DOI
  12. Lenaerts, 2006, Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system, Hepatology, 44, 844, 10.1002/hep.21355 · doi:10.1002/hep.21355
  13. Singh, 2013, Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study, Am J Gastroenterol, 108, 560, 10.1038/ajg.2013.9 · doi:10.1038/ajg.2013.9
  14. Tandon, 2009, The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study, Liver Int, 29, 169, 10.1111/j.1478-3231.2008.01778.x · doi:10.1111/j.1478-3231.2008.01778.x
  15. Badillo, 2014, Hepatic hydrothorax. Clinical features, management, and outcomes in 77 patients and review of the literature, Medicine, 93, 135, 10.1097/MD.0000000000000025 · doi:10.1097/md.0000000000000025
  16. Garbuzenko, 2017, Hepatic hydrothorax: An update and review of the literature, World J Hepatol, 1197, 10.4254/wjh.v9.i31.1197 · doi:10.4254/wjh.v9.i31.1197
  17. Zenda, 1998, Detection of diaphragmatic defect as the cause of severe hepatic hydrothorax with magnetic resonance imaging, Am J Gastroenterol, 9, 2288, 10.1111/j.1572-0241.1998.00639.x · doi:10.1111/j.1572-0241.1998.00639.x
  18. Hewett, 2016, Diagnosis of isolated hepatic hydrothorax using peritoneal scintigraphy, Hepatology, 64, 1364, 10.1002/hep.28634 · doi:10.1002/hep.28634
  19. Alonso, 2010, Pleural effusion in liver disease, Semin Respir Crit Care Med, 31, 698, 10.1055/s-0030-1269829 · doi:10.1055/s-0030-1269829
  20. Xiol, 2005, Liver transplantation in patients with hepatic hydrothorax, Transpl Int, 18, 672, 10.1111/j.1432-2277.2005.00116.x · doi:10.1111/j.1432-2277.2005.00116.x
  21. Sersté, 2010, The impact of preoperative hepatic hydrothorax on the outcome of adult liver transplantation, Eur J Gastroenterol Hepatol, 22, 207, 10.1097/MEG.0b013e3283311140 · doi:10.1097/meg.0b013e3283311140
  22. Hou, 2016, Effectiveness and safety of pleurodesis for hepatic hydrothorax: A systematic review and meta-analysis, Dig Dis Sci, 61, 3321, 10.1007/s10620-016-4260-9 · doi:10.1007/s10620-016-4260-9
  23. Huang, 2016, Thoracoscopic mesh repair of diaphragmatic defects in hepatic hydrothorax: A 10-year experience, Ann Thorac Surg, 101, 1921, 10.1016/j.athoracsur.2015.11.023 · doi:10.1016/j.athoracsur.2015.11.023
  24. Cordoba, 2010, Hyponatremic and hepatic encephalopathies: similarities, differences and coexistence, Metab Brain Dis, 25, 73, 10.1007/s11011-010-9172-3 · DOI
  25. Garcia-Pagan, 2008, Review article: the modern management of portal hypertension–primary and secondary prophylaxis of variceal bleeding in cirrhotic patients, Aliment Pharmacol Ther, 28, 178, 10.1111/j.1365-2036.2008.03729.x · doi:10.1111/j.1365-2036.2008.03729.x
  26. Li, 2016, Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis, BMJ Open, 6, e010902, 10.1136/bmjopen-2015-010902 · doi:10.1136/bmjopen-2015-010902
  27. Payance, 2016, Lack of clinical or haemodynamic rebound after abrupt interruption of beta-blockers in patients with cirrhosis, Aliment Pharmacol Ther, 43, 966, 10.1111/apt.13577 · doi:10.1111/apt.13577
  28. Villanueva, 2014, Optimizing general management of acute variceal bleeding in cirrhosis, Curr Hepatol Rep, 13, 198, 10.1007/s11901-014-0241-7 · doi:10.1007/s11901-014-0241-7
  29. Avgerinos, 1997, Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial, Lancet, 350, 1495, 10.1016/S0140-6736(97)05099-X · doi:10.1016/s0140-6736(97)05099-x
  30. Azam, 2012, Short course adjuvant terlipressin in acute variceal bleeding: a randomized double blind dummy controlled trial, J Hepatol, 56, 819, 10.1016/j.jhep.2011.11.019 · doi:10.1016/j.jhep.2011.11.019
  31. Rios Castellanos, 2015, Endoscopic injection of cyanoacrylate glue vs. other endoscopic procedures for acute bleeding gastric varices in people with portal hypertension, Cochrane Database Syst Rev, 5, CD010180
  32. Thuluvath, 2002, Portal Hypertensive gastropathy, Am J Gastroenterol, 97, 2973, 10.1111/j.1572-0241.2002.07094.x · doi:10.1111/j.1572-0241.2002.07094.x
  33. Yoshikawa, 1998, Effects of endoscopic variceal ligation on portal hypertensive gastropathy and gastric mucosal blood flow, Am J Gastroenterol, 93, 71, 10.1111/j.1572-0241.1998.071_c.x · doi:10.1111/j.1572-0241.1998.071_c.x
  34. Urrunaga, 2014, Portal hypertensive gastropathy and colopathy, Clin Liver Dis, 18, 389, 10.1016/j.cld.2014.01.008 · doi:10.1016/j.cld.2014.01.008
  35. Hosking, 1987, The role of propranolol in congestive gastropathy of portal hypertension, Hepatology, 7, 437, 10.1002/hep.1840070304 · doi:10.1002/hep.1840070304
  36. Ripoll, 2007, Treatment of gastropathy and gastric antral vascular ectasia in patients with portal hypertension, Curr Treat Options Gastroenterol, 10, 483, 10.1007/s11938-007-0048-5 · doi:10.1007/s11938-007-0048-5
  37. Kamath, 2000, Gastric Mucosal Responses to intrahepatic portosystemic shunting in patients with cirrhosis, Gastroenterology, 118, 905, 10.1016/S0016-5085(00)70176-4 · doi:10.1016/s0016-5085(00)70176-4
  38. Rios, 2015, Endoscopic injection of cyanoacrylate glue vs. other endoscopic procedures for acute bleeding gastric varices in people with portal hypertension, Cochrane Database Syst Rev, 5, CD010180
  39. Runyon, 2003, The evolution of ascitic fluid analysis in the diagnosis of spontaneous bacterial peritonitis. Runyon BA, Am J Gastroenterol, 98, 1675, 10.1111/j.1572-0241.2003.07600.x · doi:10.1111/j.1572-0241.2003.07600.x
  40. Gülberg, 2007, Insufficient sensitivity of reagent strips for spontaneous bacterial peritonitis, Hepatology, 46, 1669, 10.1002/hep.21856 · doi:10.1002/hep.21856
  41. Chen, 2011, Outcome predictors of cirrhotic patients with spontaneous bacterial empyema, Liver Int, 31, 417, 10.1111/j.1478-3231.2010.02447.x · doi:10.1111/j.1478-3231.2010.02447.x
  42. Garioud, 2017, J Clin Gastroenterol, 51, 831, 10.1097/MCG.0000000000000735 · doi:10.1097/mcg.0000000000000735
  43. Krag, 2010, Fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis, Am J Gastroenterol, 105, 1444, 10.1038/ajg.2010.126 · doi:10.1038/ajg.2010.126
  44. Arvaniti, 2010, Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis, Gastroenterology, 139, 1256, 10.1053/j.gastro.2010.06.019 · DOI · Paper page
  45. Fiore, 2017, Risk of spontaneousfungalperitonitis in hospitalized cirrhotic patients with ascites: a systematic review of observational studies and meta-analysis, Minerva Anestesiol, 83, 1309, 10.23736/S0375-9393.17.12034-1 · doi:10.23736/s0375-9393.17.12034-1
  46. Piano, 2017, Why and how to measure renal function in patients with liver disease, Liver Int, 37, 116, 10.1111/liv.13305 · doi:10.1111/liv.13305
  47. Roy, 1998, Glomerular filtration rate measurement in cirrhotic patients with renal failure, Clin Nephrol, 50, 342
  48. de Carvalho, 2012, Acute kidney injury network criteria as a predictor of hospital mortality in cirrhotic patients with ascites, J Clin Gastroenterol, 46, 21, 10.1097/MCG.0b013e31822e8e12 · doi:10.1097/mcg.0b013e31822e8e12
  49. 2012, Clinical practice guideline for the evaluation and management of chronic kidney disease, Kidny Int, 2013, 1
  50. Guevara, 2004, Effects of contrast media on renal function in patients with cirrhosis: a prospective study, Hepatology, 40, 646, 10.1002/hep.20373 · doi:10.1002/hep.20373
  51. Umgelter, 2009, Renal resistive index and renal function before and after paracentesis in patients with hepatorenal syndrome and tense ascites, Intensive Care Med, 35, 152, 10.1007/s00134-008-1253-y · doi:10.1007/s00134-008-1253-y
  52. Umgelter, 2008, Effects of plasma expansion with albumin and paracentesis on haemodynamics and kidney function in critically ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncontrolled trial, Critical care, 12, R4, 10.1186/cc6765 · doi:10.1186/cc6765
  53. Qasem, 2014, Urinary biomarkers of acute kidney injury in patients with liver cirrhosis, ISRN Nephrol, 2014, 376795, 10.1155/2014/376795 · doi:10.1155/2014/376795
  54. Huelin, 2017, New diagnostic algorithm of acute kidney injury in cirrhosis that includes categorization of stage 1 and assessment of urine NGAL. Relevance for the differential diagnosis and clinical outcomes, J Hepatol, 66, S11, 10.1016/S0168-8278(17)30283-0 · doi:10.1016/s0168-8278(17)30283-0
  55. Wadei, 2008, Kidney allocation to liver transplant candidates with renal failure of undetermined etiology: role of percutaneous renal biopsy, Am J Transplant, 8, 2618, 10.1111/j.1600-6143.2008.02426.x · doi:10.1111/j.1600-6143.2008.02426.x
  56. Bairaktari, 2001, Partially reversible renal tubular damage in patients with obstructive jaundice, Hepatology, 33, 1365, 10.1053/jhep.2001.25089 · doi:10.1053/jhep.2001.25089
  57. van Slambrouck, 2013, Bile cast nephropathy is a common pathologic finding fo kidney injury associated with severe liver dysfunction, Kidney Int, 84, 192, 10.1038/ki.2013.78 · doi:10.1038/ki.2013.78
  58. Moreau, 2002, Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study, Gastroenterology, 122, 923, 10.1053/gast.2002.32364 · doi:10.1053/gast.2002.32364
  59. Gerbes, 2009, Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration, Gastroenterology, 137, 1179, 10.1053/j.gastro.2009.03.064 · doi:10.1053/j.gastro.2009.03.064
  60. Piano, 2011, Continuousrecurrenceof type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: a new exception to MELD score in the allocation system to liver transplantation?, J Hepatol, 55, 491, 10.1016/j.jhep.2011.02.002 · doi:10.1016/j.jhep.2011.02.002
  61. Gow, 2016, Outpatient terlipressin infusion for the treatment of refractory ascites, Am J Gastroenterol, 111, 1041, 10.1038/ajg.2016.168 · doi:10.1038/ajg.2016.168
  62. Duvoux, 2002, Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study, Hepatology, 36, 374, 10.1053/jhep.2002.34343 · doi:10.1053/jhep.2002.34343
  63. Esrailian, 2007, Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome, Dig Dis Sci, 52, 742, 10.1007/s10620-006-9312-0 · doi:10.1007/s10620-006-9312-0
  64. Brensing, 2000, Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study, Gut, 47, 288, 10.1136/gut.47.2.288 · doi:10.1136/gut.47.2.288
  65. Testino, 2003, Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation, Hepatogastroenterology, 50, 1753
  66. Sourianarayanane, 2014, Management and outcome in hepatorenal syndrome: need for renal replacement therapy in non-transplanted patients, Int Urol Nephrol, 46, 793, 10.1007/s11255-013-0527-7 · doi:10.1007/s11255-013-0527-7
  67. Trebicka, 2016, Predisposing factors in acute-on-chronic liver failure, Semin Liver Dis, 36, 167, 10.1055/s-0036-1583195 · doi:10.1055/s-0036-1583195
  68. Silva, 2015, Single-centre validation of the EASL-CLIF consortium definition of acute-on-chronic liver failure and CLIF-SOFA for prediction of mortality in cirrhosis, Liver Int, 35, 1516, 10.1111/liv.12597 · doi:10.1111/liv.12597
  69. Lee, 2015, CLIF-SOFA scoring system accurately predicts short-term mortality in acutely decompensated patients with alcoholic cirrhosis: a retrospective analysis, Liver Int, 35, 46, 10.1111/liv.12683 · DOI
  70. Chen, 2014, Dexamethasone in outcome of patients with hepatitis B virus-related acute-on-chronic liver failure, J Gastroenterol Hepatol, 29, 800, 10.1111/jgh.12454 · doi:10.1111/jgh.12454
  71. Guo, 2016, Short-term efficacy of treating hepatitis B virus-related acute-on-chronic liver failure based on cold pattern differentiation with hot herbs: A randomized controlled trial, Chin J Integr Med, 22, 573, 10.1007/s11655-016-2582-2 · doi:10.1007/s11655-016-2582-2
  72. De, 2003, Cardiac dysfunction in portal hypertension among patients with cirrhosis and non-cirrhotic portal fibrosis, J Hepatol, 39, 315, 10.1016/S0168-8278(03)00271-X · doi:10.1016/s0168-8278(03)00271-x
  73. Grose, 1995, Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis, J Hepatol, 22, 326, 10.1016/0168-8278(95)80286-X · doi:10.1016/0168-8278(95)80286-x
  74. Kim, 2010, Dobutamine stress echocardiography for evaluating cirrhotic cardiomyopathy in liver cirrhosis, Korean J Hepatol, 16, 376, 10.3350/kjhep.2010.16.4.376 · doi:10.3350/kjhep.2010.16.4.376
  75. Kozor, 2016, Insight into hypertrophied hearts: a cardiovascular magnetic resonance study of papillary muscle mass and T1 mapping, Eur Heart J Cardiovasc Imaging, 18, 1034, 10.1093/ehjci/jew187 · doi:10.1093/ehjci/jew187
  76. Ngu, 2016, Cardiac remodelling identified by cardiovascular magnetic resonance in patients with hepatitis C infection and liver disease, Int J Cardiovasc Imaging, 32, 629, 10.1007/s10554-015-0824-6 · doi:10.1007/s10554-015-0824-6
  77. Trevisani, 2012, QT interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis, Liver Int, 32, 1510, 10.1111/j.1478-3231.2012.02847.x · doi:10.1111/j.1478-3231.2012.02847.x
  78. Zhao, 2016, Prevalence, risk factors and in-hospital outcomes of QTc interval prolongation in liver cirrhosis, Am J Med Sci, 352, 285, 10.1016/j.amjms.2016.06.012 · doi:10.1016/j.amjms.2016.06.012
  79. Raevens, 2014, Prevalence and outcome of diastolic dysfunction in liver transplantation recipients, Acta Cardiol, 69, 273, 10.1080/AC.69.3.3027830 · doi:10.1080/ac.69.3.3027830
  80. Saner, 2011, High brain-natriuretic peptide level predicts cirrhotic cardiomyopathy in liver transplant patients, Transpl Int, 24, 425, 10.1111/j.1432-2277.2011.01219.x · doi:10.1111/j.1432-2277.2011.01219.x
  81. Alexopoulou, 2012, Diastolic myocardial dysfunction does not affect survival in patients with cirrhosis, Transpl Int, 25, 1174, 10.1111/j.1432-2277.2012.01547.x · doi:10.1111/j.1432-2277.2012.01547.x
  82. Machicao, 2014, Pulmonary complications in chronic liver disease, Hepatology, 59, 1627, 10.1002/hep.26745 · doi:10.1002/hep.26745
  83. Kaymakoglu, 2003, Hepatopulmonary syndrome in noncirrhotic portal hypertensive patients, Dig Dis Sci, 48, 556, 10.1023/A:1022549018807 · doi:10.1023/a:1022549018807
  84. Rodríguez-Roisin, 1992, The hepatopulmonary syndrome: new name, old complexities, Thorax, 47, 897, 10.1136/thx.47.11.897 · doi:10.1136/thx.47.11.897
  85. Fallon, 2000, Pulmonary dysfunction in chronic liver disease, Hepatology, 32, 859, 10.1053/jhep.2000.7519 · doi:10.1053/jhep.2000.7519
  86. Schraufnagel, 2006, Structural and pathologic changes in the lung vasculature in chronic liver disease, Clin Chest Med, 17, 1, 10.1016/S0272-5231(05)70295-1 · doi:10.1016/s0272-5231(05)70295-1
  87. Boryczka, 2015, Influence of an upright body position on the size of intrapulmonary blood shunts in patients with advanced liver cirrhosis, J Physiol Pharmacol, 66, 855
  88. Fallon, 1997, The role of endothelial nitric oxide synthase in the pathogenesis of a rat model of hepatopulmonary syndrome, Gastroenterology, 113, 606, 10.1053/gast.1997.v113.pm9247483 · doi:10.1053/gast.1997.v113.pm9247483
  89. Luo, 2004, ET-1 and TNF- alpha in HPS: analysis in prehepatic portal hypertension and biliary and nonbiliary cirrhosis in rats, Am J Physiol Gastrointest Liver Physiol, 286, G294, 10.1152/ajpgi.00298.2003 · doi:10.1152/ajpgi.00298.2003
  90. Ling, 2004, The role of endothelin-1 and the endothelin B receptor in the pathogenesis of hepatopulmonary syndrome in the rat, Hepatology, 39, 1593, 10.1002/hep.20244 · doi:10.1002/hep.20244
  91. Tang, 2007, Modulation of pulmonary endothelial endothelin B receptor expression and signaling: implications for experimental hepatopulmonary syndrome, Am J Physiol Lung Cell Mol Physiol, 292, L1467, 10.1152/ajplung.00446.2006 · doi:10.1152/ajplung.00446.2006
  92. Frossard, 2007, Opposite regulation of endothelial NO synthase by HSP90 and caveolin in liver and lungs of rats with hepatopulmonary syndrome, Am J Physiol Gastrointest Liver Physiol, 293, G864, 10.1152/ajpgi.00136.2007 · doi:10.1152/ajpgi.00136.2007
  93. Chang, 2015, Rosuvastatin improves hepatopulmonary syndrome through inhibition of inflammatory angiogenesis of lung, Clin Sci, 129, 449, 10.1042/CS20140622 · doi:10.1042/cs20140622
  94. Rodriquez-Roisin, 2005, ERS (European Respiratory Society) Task ForcePHD Scientific Committee. Highlights of the ERS task force on pulmonary-hepatic vascular disorders (PHD), J Hepatol, 42, 924, 10.1016/j.jhep.2005.03.002 · doi:10.1016/j.jhep.2005.03.002
  95. Hoerning, 2014, Pulse oximetry is insufficient for timely diagnosis of hepatopulmonary syndrome in children with liver cirrhosis, J Pediatr, 164, 546, 10.1016/j.jpeds.2013.10.070 · doi:10.1016/j.jpeds.2013.10.070
  96. Köksal, 2006, Evaluation of intrapulmonary vascular dilatations with high-resolution computed thorax tomography in patients with hepatopulmonary syndrome, J Clin Gastroenterol, 40, 77, 10.1097/01.mcg.0000190775.57903.86 · doi:10.1097/01.mcg.0000190775.57903.86
  97. Lee, 1999, Hypoxemia and liver cirrhosis (hepatopulmonary syndrome) in eight patients: comparison of the central and peripheral pulmonary vasculature, Radiology, 211, 549, 10.1148/radiology.211.2.r99ma46549 · doi:10.1148/radiology.211.2.r99ma46549
  98. Abrams, 1995, Diagnostic utility of contrast echocardiography and lung perfusion scan in patients with hepatopulmonary syndrome, Gastroenterology, 109, 1283, 10.1016/0016-5085(95)90589-8 · doi:10.1016/0016-5085(95)90589-8
  99. Wolfe, 1977, Hypoxemia of cirrhosis: detection of abnormal small pulmonary vascular channels by a quantitative radionuclide method, Am J Med, 63, 746, 10.1016/0002-9343(77)90161-9 · doi:10.1016/0002-9343(77)90161-9
  100. Kalambokis, 2010, Pitfalls in the assessment of intrapulmonary shunt using lung perfusion scintigraphy in patients with cirrhosis, Liver Int, 31, 138, 10.1111/j.1478-3231.2010.02330.x · doi:10.1111/j.1478-3231.2010.02330.x
  101. Kochar, 2011, Serial pulse oximetry in hepatopulmonary syndrome, Dig Dis Sci, 56, 1862, 10.1007/s10620-011-1600-7 · doi:10.1007/s10620-011-1600-7
  102. Tanikella, 2008, Pilot study of pentoxifylline in hepatopulmonary syndrome, Liver Transpl, 14, 1199, 10.1002/lt.21482 · doi:10.1002/lt.21482
  103. Gupta, 2008, Pentoxyfylline therapy for hepatopulmonary syndrome: a piloto study, Arch Intern Med, 168, 1820, 10.1001/archinte.168.16.1820 · doi:10.1001/archinte.168.16.1820
  104. De, 2010, The role of garlic in hepatopulmonary syndrome: a randomized controlled trial, Can J Gastroenterol, 24, 183, 10.1155/2010/349076 · doi:10.1155/2010/349076
  105. Tsauo, 2015, Role of transjugular intrahepatic portosystemic shunts in the management of hepatopulmonary syndrome: a systemic literature review, J Vasc Interv Radiol, 26, 1266, 10.1016/j.jvir.2015.04.017 · doi:10.1016/j.jvir.2015.04.017
  106. Poterucha, 1995, Failure of hepatopulmonary syndrome to resolve after liver transplantation and successful treatment with embolotherapy, Hepatology, 21, 96, 10.1002/hep.1840210117 · doi:10.1002/hep.1840210117
  107. Fallon, 2006, Model for end-stage liver disease (MELD) exception for hepatopulmonary syndrome, Liver Transpl, 12, S105, 10.1002/lt.20971 · doi:10.1002/lt.20971
  108. Fleming, 2008, Hepatopulmonary syndrome use of extracorporeal life support for life-threatening hypoxia following liver transplantation, Liver Transpl, 14, 966, 10.1002/lt.21477 · doi:10.1002/lt.21477
  109. Monsel, 2011, Extracorporeal membrane oxygenation as a brifge to liver trnsplantation for acute respiratory distress syndrome-induced life-threatening hypoxemia aggravated by hepatopulmonary syndrome, Crit Care, 15, R234, 10.1186/cc10476 · doi:10.1186/cc10476
  110. Chihara, 2011, Immediate nonivasive ventilation may improve mortality in patients with hepatopulmonary syndrome after liver transplantation, Liver Transpl, 17, 44, 10.1002/lt.22207 · doi:10.1002/lt.22207
  111. Torregrosa, 2001, Role of Doppler echocardiography in the assessment of portopulmonary hypertension in liver transplantation candidates, Transplantation, 71, 572, 10.1097/00007890-200102270-00015 · doi:10.1097/00007890-200102270-00015
  112. Cotton, 2002, Role of echocardiography in detecting portopulmonary hypertension in liver transplant candidates, Liver Transpl, 8, 1051, 10.1053/jlts.2002.35554 · doi:10.1053/jlts.2002.35554
  113. Paulus, 2013, Oestrogen and sexual Dimorphism of pulmonary arterial hypertension; a transitional challenge, Eur Respir J, 41, 1014, 10.1183/09031936.00021713 · doi:10.1183/09031936.00021713
  114. Condino, 2005, Portopulmonary hypertension in pediatric patients, J Pediatr, 147, 20, 10.1016/j.jpeds.2005.02.019 · doi:10.1016/j.jpeds.2005.02.019
  115. Ricci, 2007, Assessment of acute pulmonary vascular reactivity in portopulmonary hypertension, Liver Transpl, 13, 1506, 10.1002/lt.21173 · doi:10.1002/lt.21173
  116. Halank, 2004, Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension, Transplantation, 77, 1775, 10.1097/01.TP.0000122420.86904.89 · doi:10.1097/01.tp.0000122420.86904.89
  117. Cadden, 2009, The use of sildenafil to treat portopulmonary hypertension prior to liver transplantation, Ann Hepatol, 8, 158, 10.1016/S1665-2681(19)31798-3 · doi:10.1016/s1665-2681(19)31798-3
  118. Fisher, 2015, Effectiveness of phosphodiesterase-5 inhibitor therapy for portopulmonary hypertension, Can Respir J, 22, 42, 10.1155/2015/810376 · doi:10.1155/2015/810376
  119. Tzathas, 2002, Sildenafil (viagra) is a risk factor for acute variceal bleeding, Am J Gastroenterol, 97, 1856, 10.1111/j.1572-0241.2002.05876.x · doi:10.1111/j.1572-0241.2002.05876.x
  120. Sussman, 2006, Successful liver transplantation following medical management of portopulmonary hypertension: a single-center series, Am J Transplant, 6, 2177, 10.1111/j.1600-6143.2006.01432.x · doi:10.1111/j.1600-6143.2006.01432.x
  121. Melgosa, 2010, Acute and long-term effects of inhaled iloprost in portopulmonary hypertension, Liver Transpl, 16, 348, 10.1002/lt.21997 · doi:10.1002/lt.21997
  122. Colombato, 1996, Haemodynamic adaptation two months after transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients, Gut, 39, 600, 10.1136/gut.39.4.600 · doi:10.1136/gut.39.4.600
  123. Yoshida, 1993, Single-lung vs. liver transplantation for the treatment of portopulmonary hypertension–a comparison of two patients, Transplantation, 55, 688
  124. Mangus, 2013, Mild to moderate pulmonary hypertension in liver transplantation, J Surg Res, 184, 1150, 10.1016/j.jss.2013.04.040 · doi:10.1016/j.jss.2013.04.040
  125. Ramsay, 1997, Severe pulmonary hypertension in liver transplant candidates, Liver Transpl Surg, 3, 494, 10.1002/lt.500030503 · doi:10.1002/lt.500030503
  126. Krowka, 2006, Model for end-stage liver disease (MELD) exception for portopulmonary hypertension, Liver Transpl, 12, S114, 10.1002/lt.20975 · doi:10.1002/lt.20975
  127. Ramsay, 2010, Portopulmonary hypertension and right heart failure in patients with cirrhosis, Curr Opin Anaesthesiol, 23, 145, 10.1097/ACO.0b013e32833725c4 · doi:10.1097/aco.0b013e32833725c4
  128. Paulsen, 1989, Considerations for anesthetic management during veno-venous bypass in adult hepatic transplantation, Anesth Analg, 68, 489, 10.1213/00000539-198904000-00012 · doi:10.1213/00000539-198904000-00012
  129. Stratta, 2013, Extracorporeal membrane oxygenation rescue therapy in a case of portopulmonary hypertension during liver transplantation: a case report, Transplant Proc, 45, 2774, 10.1016/j.transproceed.2013.07.001 · doi:10.1016/j.transproceed.2013.07.001
  130. Khaderi, 2014, Long-term follow-up of portopulmonary hypertension patients after liver transplantation, Liver Transpl, 20, 724, 10.1002/lt.23870 · doi:10.1002/lt.23870

Cited by

See all 2,905

Metadata

Authors
Angeli, P., Bernardi, M., Villanueva, C., Francoz, C., Mookerjee, R. P., Trebicka, J., Krag, A., Laleman, W., & Gines, P.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2018-08
Volume
69
Issue
2
Pages
406-460
ISSN
0168-8278 (ISSN-L)
OpenAlex
W2802906787
Cited by
2,905
References
479
FWCI
132.14
Type
journal article
Language
en
Update notices
erratum (2018-11-01)
Open access
bronze
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.